Valuation: Shamrock Industrial Company Limited

Market Cap 148M 1.55M 1.39M 1.29M 1.17M 2.18M 2.2M 15.39M 6.13M 77.36M 5.82M 5.7M 246M P/E 2025
-53.4x
P/E 2026 -10.7x
Enterprise Value 154M 1.62M 1.45M 1.34M 1.22M 2.27M 2.3M 16.07M 6.4M 80.76M 6.08M 5.95M 256M EV / Sales 2025
-
EV / Sales 2026 609x
Free-Float
48.09%
Yield 2025 *
-
Yield 2026 -
08-14 Shamrock Industrial Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-29 Shamrock Industrial Company Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-12 Shamrock Industrial Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
12-22 Shamrock Industrial Company Limited Approves the Proposals for Incorporation of Wholly Owned Subsidiaries CI
12-22 Shamrock Industrial Company Limited Approves the Proposals for Incorporation of Wholly Owned Subsidiaries CI
12-11 Shamrock Industrial Company Limited Announces Incorporation of Wholly Owned Subsidiary HODL Energy Private Limited in India CI
11-14 Shamrock Industrial Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-13 Lotus Excel Wealth Creators LLP, HODL Systems LLP, Bagepalli Vijaykumar Harish and Rattan Kapoor completed the acquisition of 0.38% stake in Shamrock Industrial Company Limited for INR 0.34 million. CI
28/10/25 Shamrock Industrial appoints Rahul Manoj Rajani as chief financial officer RE
28/10/25 Shamrock Industrial Company Limited Approves Appointment of Rahul Manoj Rajani as Chief Financial Officer, Effective October 28, 2025 CI
28/10/25 Shamrock Industrial Company Limited Announces Board Appointments, Effective October 28, 2025 CI
17/10/25 Shamrock Industrial Company Limited Announces Resignation of Jitesh Rameshchandra Khokhani as Chief Financial Officer, with Effect from Closure of Business Hours of October 16, 2025 CI
17/10/25 Shamrock Industrial Company Limited Announces Board Resignations, with Effect from October 16, 2025 CI
3 months+10.19%
6 months+27.46%
Current year+40.46%
1 week 27.25
Extreme 27.25
27.25
1 month 27.25
Extreme 27.25
27.25
Current year 19.4
Extreme 19.4
27.25
1 year 17.6
Extreme 17.6
27.25
3 years 4.8
Extreme 4.8
27.25
5 years 3.16
Extreme 3.16
27.25
10 years 3.16
Extreme 3.16
27.25
Manager TitleAgeSince
Chief Executive Officer - 16/10/2025
Director of Finance/CFO - 28/10/2025
Chief Operating Officer - 28/10/2025
Director TitleAgeSince
Director/Board Member - 22/06/2021
Director/Board Member - 21/04/2022
Director/Board Member - 16/10/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+54.83%+384.01% 1.55M
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
+0.71%+2.32%+54.07%+66.27% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+3.23%+3.54%+35.47%+57.67% 294B
+1.98%+0.20%+3.55%+27.29% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +1.92%+1.25%+42.74%+107.48% 403.72B
Weighted average by Cap. +2.44%+1.50%+45.04%+89.29%

Financials

2025 2026
Net sales - 201K 2.11K 1.89K 1.75K 1.59K 2.96K 3K 20.93K 8.34K 105K 7.92K 7.75K 334K
Net income -1.26M -13.23K -11.87K -10.97K -9.94K -18.57K -18.79K -131K -52.26K -659K -49.65K -48.6K -2.09M -10.87M -114K -102K -94.64K -85.71K -160K -162K -1.13M -451K -5.69M -428K -419K -18.05M
Net Debt -137K -1.44K -1.29K -1.19K -1.08K -2.02K -2.04K -14.27K -5.68K -71.69K -5.4K -5.28K -228K 6.49M 68.19K 61.18K 56.56K 51.22K 95.7K 96.86K 676K 269K 3.4M 256K 250K 10.79M
Projected Income Statement - Annual - Shamrock Industrial Company Limited
Logo Shamrock Industrial Company Limited
Shamrock Industrial Company Limited is an India-based pharmaceuticals company. The Company offers a diverse range of manufacturing of pharmaceuticals and drugs products and allied business activities. It offers its products for various therapeutic uses, including anti-coagulants (anti-platelet), radio-protective agents, platelet regulator, anti-depressants, anti-neo plastics and immunosuppressants, antihistamines, sympathomimetics, anti-hypertensives, diuretic, anti-diabetic, calcium regulating agents, local anesthetics and anti-bacterial. Its active pharmaceutical ingredient (API) product list (manufactured) includes acenocomarol, amifostine, ciclopirox, cilazapril, losartan potassium, metaxalone, metoprolol succinate and pregabalin. The Company's API product list (contract manufactured) includes abacavir, acarbose, oxaliplatin, oxaprozin, finasteride, frusemide and colchicine.
Employees
1
Date Price Change Volume
26/10/26 ₹27.25 0.00% 24,278
  1. Stock Market
  2. Stocks
  3. SHAMROIN Stock